Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoAspMet trial in locally advanced rectal cancer
2024-519007-10-00Phase 3Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Oct 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin and metformin in rectal adenocarcinoma (4 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Good pathological response. Planned start Oct 2020; status: authorised.
02
Drugs
aspirinmetformin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2024-519007-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519007-10-00.